



南京中生聯合股份有限公司  
NANJING SINOLIFE UNITED COMPANY LIMITED\*

(a joint stock limited liability company incorporated in the People's Republic of China)  
(於中華人民共和國註冊成立的股份有限公司)

**Stock Code** 股份代號: 3332

INTERIM REPORT  
中期報告 **2023**



\* For identification purposes only  
僅供識別



# CONTENTS 目錄

2	Corporate Information	公司資料
4	Financial Highlights	財務摘要
5	Product Information	產品資料
10	Management Discussion and Analysis	管理層討論及分析
16	Other Information	其他資料
22	Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	中期簡明綜合損益及其他全面收益表
23	Interim Condensed Consolidated Statement of Financial Position	中期簡明綜合財務狀況表
24	Interim Condensed Consolidated Statement of Changes in Equity	中期簡明綜合權益變動表
25	Interim Condensed Consolidated Statement of Cash Flows	中期簡明綜合現金流量表
26	Notes to the Interim Condensed Consolidated Financial Statements	中期簡明綜合財務報表附註



# CORPORATE INFORMATION

## 公司資料

### DIRECTORS

#### Executive Directors

Mr. Gui Pinghu (桂平湖) (*Chairman*)  
Ms. Zhang Yuan (張源) (*Chief Executive Officer*)  
Ms. Zhu Feifei (朱飛飛)

#### Independent Non-executive Directors

Mr. Yu Bo (余波)  
Ms. Cai Tianchen (蔡天晨)  
Mr. Wang Wei (王瑋)

### AUDIT COMMITTEE

Ms. Cai Tianchen (蔡天晨) (*Chairman*)  
Mr. Yu Bo (余波)  
Mr. Wang Wei (王瑋)

### REMUNERATION COMMITTEE

Mr. Wang Wei (王瑋) (*Chairman*)  
Ms. Cai Tianchen (蔡天晨)  
Ms. Zhu Feifei (朱飛飛)

### NOMINATION COMMITTEE

Mr. Yu Bo (余波) (*Chairman*)  
Mr. Wang Wei (王瑋)  
Ms. Zhang Yuan (張源)

### STRATEGY AND DEVELOPMENT COMMITTEE

Mr. Gui Pinghu (桂平湖) (*Chairman*)  
Mr. Yu Bo (余波)  
Ms. Cai Tianchen (蔡天晨)

### JOINT COMPANY SECRETARIES

Ms. Zhi Hui (支卉)  
Ms. Kam Mei Ha Wendy (甘美霞) *FCG, HKFCG*

### REGISTERED OFFICE AND HEADQUARTERS

4/F, Building 3, 3 Qingma Road  
Qixia District  
Nanjing, Jiangsu Province  
The People's Republic of China (the "PRC")

### PRINCIPAL PLACE OF BUSINESS IN HONG KONG

40th Floor, Jardine House  
1 Connaught Place  
Hong Kong

### 董事

#### 執行董事

桂平湖先生(董事長)  
張源女士(首席執行官)  
朱飛飛女士

#### 獨立非執行董事

余波先生  
蔡天晨女士  
王瑋先生

### 審核委員會

蔡天晨女士(主席)  
余波先生  
王瑋先生

### 薪酬委員會

王瑋先生(主席)  
蔡天晨女士  
朱飛飛女士

### 提名委員會

余波先生(主席)  
王瑋先生  
張源女士

### 戰略及發展委員會

桂平湖先生(主席)  
余波先生  
蔡天晨女士

### 聯席公司秘書

支卉女士  
甘美霞女士 *FCG, HKFCG*

### 註冊辦事處及總部

中華人民共和國(「中國」)  
江蘇省南京市  
栖霞區  
青馬路3號3號樓4樓

### 香港主要營業地點

香港  
康樂廣場1號  
怡和大廈40樓

# CORPORATE INFORMATION

## 公司資料

### AUTHORISED REPRESENTATIVES

Mr. Gui Pinghu (桂平湖)  
Ms. Kam Mei Ha Wendy (甘美霞) FCG, HKFCG

### LEGAL ADVISERS

*As to Hong Kong law*  
Chiu & Partners  
40th Floor, Jardine House  
1 Connaught Place  
Hong Kong

*As to PRC law*  
King & Wood Mallesons  
32/F, One IFC  
No. 347 Jiangdong Middle Road  
Nanjing, Jiangsu Province  
The PRC

### H SHARE REGISTRAR

Computershare Hong Kong Investor Services Limited  
Shops 1712–1716, 17th Floor  
Hopewell Centre  
183 Queen's Road East  
Wanchai  
Hong Kong

### PRINCIPAL BANKERS

Shanghai Pudong Development Bank Cheng Dong Branch  
137 Daguang Road  
Nanjing, Jiangsu Province  
The PRC

Agricultural Bank of China Ma Qun Branch  
99 Huanling Road  
Qixia District  
Nanjing, Jiangsu Province  
The PRC

### AUDITOR

Ernst & Young  
*Certified Public Accountants*  
*Registered Public Interest Entity Auditor*  
27/F, One Taikoo Place  
979 King's Road  
Quarry Bay, Hong Kong

### STOCK CODE

3332

### COMPANY'S WEBSITE

[www.zs-united.com](http://www.zs-united.com)

### 授權代表

桂平湖先生  
甘美霞女士 FCG, HKFCG

### 法律顧問

*香港法律*  
趙不渝馬國強律師事務所  
香港  
康樂廣場1號  
怡和大廈40樓

*中國法律*  
金杜律師事務所  
中國  
江蘇省南京市  
江東中路347號  
國金中心一期32樓

### H股證券登記處

香港中央證券登記有限公司  
香港  
灣仔  
皇后大道東183號  
合和中心  
17樓1712–1716號舖

### 主要往來銀行

上海浦東發展銀行城東支行  
中國  
江蘇省南京市  
大光路137號

中國農業銀行馬群支行  
中國  
江蘇省南京市  
栖霞區  
環陵路99號

### 核數師

安永會計師事務所  
*執業會計師*  
*註冊公眾利益實體核數師*  
香港鰂魚涌  
英皇道979號  
太古坊1座27樓

### 股份代號

3332

### 公司網站

[www.zs-united.com](http://www.zs-united.com)

# FINANCIAL HIGHLIGHTS

## 財務摘要

### FINANCIAL HIGHLIGHTS FOR THE FIRST HALF OF 2023

- Revenue increased by approximately 78.3% to approximately RMB218.9 million (First half of 2022: approximately RMB122.8 million)
- Gross profit increased by approximately 103.5% to approximately RMB145.9 million (First half of 2022: approximately RMB71.7 million)
- Profit for the period was approximately RMB27.8 million (First half of 2022: loss of approximately RMB5.2 million)
- Basic earnings per share was approximately RMB2.94 cents (First half of 2022: loss per share approximately RMB0.55 cent)
- The Board has resolved not to declare any interim dividend for the six months ended 30 June 2023 (First half of 2022: Nil)

### 2023 年上半年財務摘要

- 收益增加約 78.3% 至約人民幣 218.9 百萬元 (2022 年上半年：約人民幣 122.8 百萬元)
- 毛利增加約 103.5% 至約人民幣 145.9 百萬元 (2022 年上半年：約人民幣 71.7 百萬元)
- 本期溢利約為人民幣 27.8 百萬元 (2022 年上半年：虧損約人民幣 5.2 百萬元)
- 每股基本盈利約為人民幣 2.94 分 (2022 年上半年：每股虧損約人民幣 0.55 分)
- 董事會已決議不派付截至 2023 年 6 月 30 日止六個月之任何中期股息 (2022 年上半年：無)



GOOD HEALTH  
好健康系列



Propolis Capsules  
蜂膠膠囊



Oyster Plus Capsules  
牡蠣精膠囊



Hi Cal™ Liquid Calcium & Vitamin D  
高鈣 — 液體鈣和維生素D



Coenzyme Q10 Capsules  
輔酶Q10膠囊



Grape Seed 55,000 Capsules  
葡萄籽55,000膠囊



1-a-day Glucosamine Capsules  
氨基葡萄糖膠囊

# PRODUCT INFORMATION

## 產品資料

### GOOD HEALTH

### 好健康系列



**Mussel 6000 Capsules**  
綠唇貽貝6000膠囊



**Milk Thistle 35,000 Capsules**  
奶薊草膠囊



**Omega 3 Fish Oil Capsules**  
魚油膠囊



**Garcinia Capsules**  
藤黃果膠囊



**Bilberry & Lutein Capsules**  
越橘葉黃素膠囊



**Joint Active with UC-II Capsules**  
骨膠原膠囊



GOOD HEALTH  
好健康系列



Gut Guard Powder  
養胃粉



Viralex Attack Capsules  
維樂士舒鼻膠囊



Viralex Revive Drink  
維樂士免疫粉



Viralex Soothe Throat Lozenges  
維樂士潤喉片



Modified Milk Powder with Lactoferrin  
乳鐵蛋白調製乳粉



Vira-Complex Powder  
維爾敏複合粉



# PRODUCT INFORMATION

## 產品資料

### GOOD HEALTH

#### 好健康系列



**Modified Milk Powder with Lactase**  
乳糖酶調製乳粉



**Calcium Iron and Zinc Nutrient Sprinkles**  
鈣鐵鋅營養包



**Probiotic Powder Solid Beverage**  
益生菌固體飲料



**Good Kids Vision Chews**  
兒童視力咀嚼片



**Kids Magnesium Chews**  
兒童鎂咀嚼片



**Kids Immune Chews**  
兒童免疫力咀嚼片

GOOD HEALTH  
好健康系列



Alage Oil DHA Kids Capsules  
兒童藻油DHA膠囊



Kids Growth Chews  
兒童成長咀嚼片



Kids Vision Chews  
兒童視力寶葉黃素咀嚼片



Gummy Candy Series  
凝膠糖果系列

# MANAGEMENT DISCUSSION AND ANALYSIS

## 管理層討論及分析

### BUSINESS REVIEW

In the first half of 2023, both the cross-border e-commerce of nutritional supplements and the distribution channels of the maternity and child series products under the Good Health brand in the PRC experienced rapid growth. The Group's revenue for the first half of 2023 amounted to approximately RMB218.9 million, increased by approximately RMB96.1 million as compared to that of approximately RMB122.8 million in the first half of 2022, representing an increase of approximately 78.3%. The gross profit margin in the first half of 2023 was approximately 66.6% as compared with that of approximately 58.4% in the first half of 2022, representing an increase of approximately 8.2%. The Group's selling and distribution expenses and administrative expenses as a percentage of sales revenue decreased by approximately 8.9% to approximately 52.8% for the first half of 2023 from approximately 61.7% for the first half of 2022. For the first half of 2023, the Group recorded profits of approximately RMB27.8 million, representing an increase in profit of approximately RMB33.0 million as compared to losses of approximately RMB5.2 million for the first half of 2022.

In the first half of 2023, the Group continued to adopt the strategies of focusing its resources on the Good Health brand and sales promotion through distributors and e-commerce channels, so as to achieve greater brand recognition of the Good Health brand in the target markets. The Group increased its investments in marketing and promotion of its cross-border e-commerce business in the PRC, and in terms of design, advertising and promotion, the Group strived to innovate, with a view to enhancing the efficiency and effectiveness of its promotional efforts. Meanwhile, more investments were made in the research and development of new products in response to customers' demands for the maternity and child series products of the Good Health brand. The Group carried out continuous brand building and promotion mainly through various channels including distributors, pharmacies, duty-free stores, and flagship stores on domestic major e-commerce platforms.

In the first half of 2023, in order to enhance market competitiveness of its products and meet evolving consumer demands, the Group adopted a market-oriented strategy for research and product development to further strengthen new products development. During the six months ended 30 June 2023, the Group launched a total of eight new products, including one New Goodhealth series product and seven Good Health series products. The new products mainly comprised Elderberry Flavored Drink, Iron-Rich Gummy, Vira-Complex Powder, Virawell Power 300, Carb Buster Citrus Bioflavonoid Plus, Men's Vitality, EinCardio, etc..

### 業務回顧

於2023年上半年，好健康品牌營養膳食補充劑跨境電商業務和嬰童系列營養產品中國地區經銷商業務，均取得快速發展。本集團於2023年上半年收益約為人民幣218.9百萬元，較2022年上半年的收益約為人民幣122.8百萬元，增加約為人民幣96.1百萬元，增長率約為78.3%。2023年上半年毛利率約為66.6%，較2022年上半年毛利率約為58.4%，增長率約為8.2%。銷售及經銷開支、行政開支對銷售收入佔比，由2022年上半年約為61.7%，減少約8.9%，至2023年上半年約為52.8%。本集團於2023年上半年錄得利潤約人民幣27.8百萬元，較2022年上半年錄得虧損約人民幣5.2百萬元，利潤增加約人民幣33.0百萬元。

於2023年上半年，本集團繼續聚焦資源於好健康品牌和通過在經銷商及電子商貿等渠道進行銷售推廣的策略，使好健康品牌在目標市場獲得更高的品牌認可度。本集團加大了中國跨境電商業務的營銷推廣投入，同時在廣告設計、宣傳及推廣方式，予以創新，力求提升宣傳推廣效率和效果。同時，針對好健康品牌母嬰系列產品的客戶需求，加大了對新產品的研發投入。本集團主要通過經銷商、藥房、旅遊免稅店、境內大型電子商貿平台旗艦店等方式進行持續的品牌建設及推廣。

於2023年上半年，為提升產品的市場競爭力及滿足不斷轉變的消費者需要，本集團採用以市場為導向的研究及產品開發策略，進一步加強對新產品的開發。於截至2023年6月30日止六個月，本集團共計推出8項新產品，包括1項紐好康系列產品及7項好健康系列產品。新產品主要包括接骨木莓風味飲品、富鐵軟糖、維爾敏複合粉、紐好康調製乳粉、碳水大師片、男士活力膠囊、高濃度魚油等。



# MANAGEMENT DISCUSSION AND ANALYSIS

## 管理層討論及分析

### FINANCIAL REVIEW

#### Results

The Group's revenue for the first half of 2023 amounted to approximately RMB218.9 million, and increased by approximately RMB96.1 million as compared to that of approximately RMB122.8 million in the first half of 2022, representing an increase of approximately 78.3%.

For the first half of 2023, the Group recorded profits of approximately RMB27.8 million, representing an increase in profit of approximately RMB33.0 million as compared to losses of approximately RMB5.2 million for the first half of 2022. The Company's earnings per share was approximately RMB2.94 cents (First half of 2022: loss per share of approximately RMB0.55 cent) based on the weighted average number of 946,298,370 (First half of 2022: 946,298,370) ordinary shares of the Company in issue during the first half of 2023.

#### Revenue

The Group's revenue for the first half of 2023 amounted to approximately RMB218.9 million, and increased by approximately RMB96.1 million as compared to that of approximately RMB122.8 million in the first half of 2022, representing an increase of approximately 78.3%. The increase in revenue was mainly attributable to the significant increase in revenue derived from both online and offline sales channels during the period.

#### Gross profit

The Group's gross profit increased by approximately RMB74.2 million from approximately RMB71.7 million in the first half of 2022 to approximately RMB145.9 million in the first half of 2023. The gross profit margin increased by approximately 8.2% from approximately 58.4% in the first half of 2022 to approximately 66.6% in the first half of 2023. The increase in gross profit margin was mainly attributable to the increase in the proportion of sales revenue from e-commerce platforms, which has higher gross profit margins, as compared to other sales channels.

#### Other income and gains

The Group's other income and gains, which mainly comprised rental income, government grants and bank interest income, increased by approximately RMB0.7 million from approximately RMB3.1 million in the first half of 2022 as compared to approximately RMB3.8 million in the first half of 2023, which was mainly due to the slight increase in property rental income and government grants.

### 財務回顧

#### 業績

本集團於2023年上半年收益約為人民幣218.9百萬元，較2022年上半年的收益約為人民幣122.8百萬元，增加約為人民幣96.1百萬元，增長率約為78.3%。

本集團於2023年上半年錄得利潤約人民幣27.8百萬元，較2022年上半年錄得虧損約人民幣5.2百萬元，利潤增長約人民幣33.0百萬元。按2023年上半年公司已發行普通股加權平均數946,298,370股(2022年上半年：946,298,370股)計算，本公司的每股盈利約為人民幣2.94分(2022年上半年：每股虧損約人民幣0.55分)。

#### 收益

本集團於2023年上半年收益約為人民幣218.9百萬元，較2022年上半年的收益約為人民幣122.8百萬元，增加約為人民幣96.1百萬元，增長率約為78.3%。收益增長主要為期內來自線上、線下銷售渠道的收入大幅增加所致。

#### 毛利

本集團於2023年上半年毛利約為人民幣145.9百萬元，較2022年上半年毛利約為人民幣71.7百萬元，增長約為人民幣74.2百萬元。2023年上半年毛利率約為66.6%，2022年上半年毛利率約為58.4%，增長率約為8.2%。毛利率增長主要為來自毛利率比其他銷售渠道更高的電子商務平台銷售收入佔比提高。

#### 其他收入和盈利

本集團的其他收入及盈利主要包括租賃收入、政府補助金及銀行利息收入，由2022年上半年約為人民幣3.1百萬元增加至2023年上半年約為人民幣3.8百萬元，增長約為人民幣0.7百萬元，主要為房產租賃收入、政府補助金略有增長。

# MANAGEMENT DISCUSSION AND ANALYSIS

## 管理層討論及分析

### Selling and distribution expenses

The Group's selling and distribution expenses increased by approximately RMB38.9 million or approximately 84.2% from approximately RMB46.2 million in the first half of 2022 to approximately RMB85.1 million in the first half of 2023. The proportion of selling and distribution expenses to sales revenue was 38.9%, which remained stable as compared to that of the first half of 2022. Such increase in selling and distribution expenses was mainly due to the Group's vigorous development of Good Health cross-border e-commerce channels by increasing its investment in marketing and promotional resources in such channels.

### Administrative expenses

The Group's administrative expenses amounted to approximately RMB30.6 million for the first half of 2023, which remained stable as compared to approximately RMB29.6 million for the first half of 2022. The proportion of administrative expenses to sales revenue decreased approximately 10.1% from approximately 24.1% in the first half of 2022 to approximately 14.0% in the first half of 2023. Such decrease in the proportion of administrative expenses to sales revenue was mainly due to the increase in sales revenue for the first half of 2023.

### Income tax expense

The Group's income tax expense increased from approximately RMB0.9 million in the first half of 2022 to approximately RMB2.0 million in the first half of 2023, representing an increase of approximately RMB1.1 million. Such increase in income tax expense was mainly due to the increase in income tax expense of Good Health Products Limited, one of the Group's subsidiaries in New Zealand, due to its corresponding increase in profit.

### Profit for the period

The revenue of the Group increased by approximately RMB96.1 million or approximately 78.3% to approximately RMB218.9 million in the first half of 2023 from approximately RMB122.8 million in the first half of 2022. Gross profit margin increased by approximately 8.2% to approximately 66.6% in the first half of 2023 from approximately 58.4% in the first half of 2022. The proportion of selling and distribution expenses and administrative expenses to sales revenue decreased by approximately 8.9% from approximately 61.7% in the first half of 2022 to approximately 52.8% in the first half of 2023. Therefore, the Group recorded a profit of approximately RMB27.8 million in the first half of 2023, representing an increase in profit of approximately RMB33.0 million as compared to a loss of approximately RMB5.2 million recorded in the first half of 2022.

### 銷售及經銷開支

本集團於2022年上半年銷售及經銷開支約為人民幣46.2百萬元，增長至2023年上半年約為人民幣85.1百萬元，增長約為人民幣38.9百萬元，增長率約為84.2%。銷售及經銷開支對銷售收入的佔比為38.9%，和2022年上半年保持穩定。銷售及經銷開支增長主要為本集團大力發展好健康跨境電子商務渠道，加大了在該等渠道的銷售宣傳推廣資源的投入。

### 行政開支

本集團於2023年上半年行政開支約為人民幣30.6百萬元，2022年上半年約為人民幣29.6百萬元，同期行政開支保持穩定。行政開支對銷售收入佔比，由2022年上半年約為24.1%，減少約10.1%，至2023年上半年約為14.0%。行政開支對銷售收入佔比減少，主要為2023年上半年銷售收入增長所致。

### 所得稅開支

本集團於2023年上半年的所得稅開支約為人民幣2.0百萬元，較2022年上半年的所得稅開支約為0.9百萬元，增加約人民幣1.1百萬元。所得稅開支增加主要為本集團在紐西蘭的其中一家附屬公司 Good Health Products Limited 的溢利增加，其所得稅開支增加。

### 期間盈利

本集團於2023年上半年收益約為人民幣218.9百萬元，較2022年上半年的收益約為人民幣122.8百萬元，增加約為人民幣96.1百萬元，增長率約為78.3%。2023年上半年毛利率約為66.6%，2022年上半年毛利率約為58.4%，增長率約為8.2%。銷售及經銷開支、行政開支對銷售收入佔比，由2022年上半年約為61.7%，減少約8.9%，至2023年上半年約為52.8%。因此，本集團於2023年上半年錄得利潤約為人民幣27.8百萬元，較2022年上半年錄得虧損約人民幣5.2百萬元，利潤增加約人民幣33.0百萬元。

# MANAGEMENT DISCUSSION AND ANALYSIS

## 管理層討論及分析

### LIQUIDITY AND CAPITAL RESOURCES

#### Cash flow

As at 30 June 2023, the Group's monetary fund decreased by approximately RMB12.6 million as compared with that of 31 December 2022 mainly due to the net cash outflow from operating activities of approximately RMB10.1 million, net cash outflow from investing activities of approximately RMB0.5 million, net cash outflow from financing activities of approximately RMB2.2 million and cash inflow from exchange effects of approximately RMB0.2 million.

#### Inventories

The Group's inventories amounted to approximately RMB114.0 million as at 30 June 2023 (as at 31 December 2022: approximately RMB75.3 million), representing an increase of approximately RMB38.7 million or approximately 51.4%. The Group's inventories include raw materials, work-in-progress, finished goods and goods merchandise. Such increase in inventories was mainly due to the increase in the reserve of raw materials and finished goods of Good Health products in New Zealand to meet the potential demand from the cross-border e-commerce platforms in the second half of 2023. Meanwhile, the Company continued to further expand its distributor channels for Good Health infant and kid's nutritional products in the PRC, of which the Lactoferrin is a star product in the distributor channels, and the Company has increased the reserves of Lactoferrin during the period to meet the increasing sales demand from the distributor channels. The inventory turnover days remained stable at approximately 233 days in the first half of 2023 (the first half of 2022: 231 days).

#### Trade receivables

The Group's trade receivables amounted to approximately RMB32.0 million as at 30 June 2023 (as at 31 December 2022: approximately RMB28.2 million), representing an increase of approximately RMB3.8 million or approximately 13.5%. Such increase was mainly due to the increase in accounts receivable as a result of the increase in sales revenue from the distributors of the Company in the PRC and the cross-border e-commerce platforms.

#### Trade payables

The Group's trade payables amounted to approximately RMB31.8 million as at 30 June 2023 (as at 31 December 2022: approximately RMB21.5 million), representing an increase of approximately RMB10.3 million or approximately 47.9%. Due to the Group's vigorous development of the cross-border e-commerce business for the Good Health brand and the rapid growth of e-commerce channel sales in the first half of 2023, the Group increased its production capacity of Good Health brand in the first half of the year to meet the market demand, resulting in an increase in the balance of trade payables to raw material suppliers.

### 流動資金和資本資源

#### 現金流量

2023年6月30日貨幣資金較2022年12月31日減少了約人民幣12.6百萬元，主要原因係：經營活動現金淨流出約人民幣10.1百萬元；投資活動現金淨流出約人民幣0.5百萬元；籌資活動現金淨流出約人民幣2.2百萬元；匯兌影響現金流入0.2百萬元。

#### 存貨

於2023年6月30日，本集團存貨約為人民幣114.0百萬元（於2022年12月31日：約人民幣75.3百萬元），增加約人民幣38.7百萬元，增長率約為51.4%。本集團的存貨包括原材料、在製品、製成品及採購品。存貨增加主要由於為滿足2023年下半年跨境電商平台的潛在需要，在紐西蘭增加了好健康產品原材料及製成品的儲備量。同時，公司繼續進一步拓展好健康嬰童類營養品在中國的經銷商渠道，其中乳鐵蛋白作為經銷商渠道的明星產品，公司本期增加對其的儲備量以應對經銷商渠道增長的銷售需求。2023年上半年，存貨周轉天數約為233天（2022年上半年：231天），存貨周轉率基礎持平。

#### 貿易應收款項

於2023年6月30日，本集團的貿易應收款項約為人民幣32.0百萬元（於2022年12月31日：約為人民幣28.2百萬元），增長約人民幣3.8百萬元，增長率約為13.5%。增長主要原因為：本公司中國經銷商以及跨境電商平台銷售收入增加，因此應收賬款有所增加。

#### 貿易應付款項

於2023年6月30日，本集團的貿易應付款項約為人民幣31.8百萬元（於2022年12月31日：約人民幣21.5百萬元），增加了約人民幣10.3百萬元，增長率約為47.9%。由於本集團大力發展好健康品牌跨境電商業務，2023年上半年電商渠道銷售的快速增長，好健康品牌上半年提高產量，以應對市場需求，因此應付原材料供應商貨款餘額增加。



# MANAGEMENT DISCUSSION AND ANALYSIS

## 管理層討論及分析

### Foreign exchange exposure

As the Group conducts in-bound transactions principally in RMB and outbound transactions principally in New Zealand dollars, United States dollars and Australian dollars, the Group had not utilised any types of financial instruments for hedging purposes as at 30 June 2023.

### Borrowings and pledge of assets

As at 30 June 2023, the Group did not have any outstanding borrowings or pledge of assets.

### Gearing position

The gearing ratio, which represented total net debt (including lease liabilities, trade payables and other payables and accruals) divided by total equity attribute to owners of the parent and net debt multiplied by 100%, was 20.8% as at 30 June 2023 (as at 31 December 2022: 23.3%).

### Capital expenditure

The Group invested approximately RMB1.1 million in the first half of 2023 (the first half of 2022: approximately RMB1.5 million) for fixed assets.

### Capital commitments and contingent liabilities

As at 30 June 2023, the Group did not have capital commitments (as at 31 December 2022: Nil). As at 30 June 2023, the Group had no material contingent liabilities (as at 31 December 2022: Nil).

## OUTLOOK

In the first half of 2023, the global economy as a whole showed signs of recovery. Major economies, such as Europe, the United States of America and China, experienced positive growth, with the global inflation rate remaining overall stable, and the employment conditions generally improving across the globe. Following the COVID-19 pandemic, China's economic and social conditions returned to the pre-pandemic level. Supported by effective macroeconomic policies, the national economy has rebounded as a whole with a steady progress in development. However, amid the complex global political and economic conditions, the foundation for sustainable domestic economic recovery and development remained unstable.

In the first half of 2023, sales revenue of the Good Health brand from e-commerce platforms and the distributor channels for infant and child series products in the PRC have both recorded significant growth, enhancing the overall profitability of the Group. Meanwhile, the Good Health brand continues with its growing influence within the industry.

### 匯兌風險

由於本集團境內業務主要以人民幣進行業務交易，境外業務主要以紐西蘭元、美元及澳元進行業務交易，因此本集團並未於2023年6月30日使用任何形式的金融工具作對沖用途。

### 借款及資產抵押

於2023年6月30日，本集團無任何未償還借款或資產抵押。

### 資產負債狀況

資產負債比率乃將總負債淨額(包括租賃負債、貿易應付款項及其他應付款項以及應計費用)除以母公司擁有人應佔總權益及負債淨額再乘以100%後呈列，於2023年6月30日為20.8%(2022年12月31日：23.3%)。

### 資本開支

於2023年上半年，本集團斥資約人民幣1.1百萬元(於2022年上半年，約人民幣1.5百萬元)投資於固定資產。

### 資本承擔及或然負債

於2023年6月30日，本集團無資產承擔(於2022年12月31日：無)。於2023年6月30日，本集團並無重大或然負債(於2022年12月31日：無)。

### 展望

2023年上半年，全球經濟整體呈現復甦態勢。主要經濟體如歐洲、美國及中國等均實現了正增長；全球通脹水平總體保持穩定；全球就業形式總體向好。中國隨著新冠疫情後，經濟社會恢復到新冠疫情前的狀態，宏觀政策顯效發力，國民經濟回升整體向好，發展穩步推進。同時，世界政治經濟形勢錯綜複雜，國內經濟持續恢復發展的基礎仍不穩固。

2023年上半年，好健康品牌在電子商務平台以及嬰童類產品中國經銷商渠道的銷售收入均取得了大幅增長，增強了本集團整體的盈利能力。同時，好健康品牌在行業內的影響力也得以不斷提升。

# MANAGEMENT DISCUSSION AND ANALYSIS

## 管理層討論及分析

In the second half of 2023, the global economy continues to face considerable uncertainties, mainly including the aftermath of the COVID-19 pandemic, escalating geopolitical conflicts, a continued trend towards deglobalisation, and high debt levels of certain countries and major corporations, which may give rise to financial risks. As a major economic powerhouse in the global economy, China is expected to maintain resilience and sustainability in its macroeconomic recovery for the second half of the year.

Looking into the second half of 2023, the Group will continue to focus on two major business segments: (i) the cross-border e-commerce in the PRC for nutritional supplements under the Good Health brand; and (ii) the offline distributor channels in the PRC for the infant and child series products under the Good Health brand. The Group will focus on: (1) increasing investments in promotion for cross-border e-commerce and distributor channels for infant and child products in the PRC, with an emphasis on the effectiveness and efficiency of these investments; (2) accelerating the research and development and launching of new products to meet the needs of target customers, so as to enhance the competitiveness of Good Health brand products and expand its sales volume; and (3) improving the supply chain management to enhance the inventory turnover rate, thereby improving the overall profitability and cash flow of the Group.

### HUMAN RESOURCES MANAGEMENT

High-caliber and dedicated staff are indispensable assets to the Group's success in the competitive market. By providing comprehensive trainings and corporate culture education periodically, the Group's employees are able to receive on-going training and knowledge development in respect of the nutritional supplements, maternity and child nutrition industry. Furthermore, the Group offers competitive remuneration packages commensurate with industry practice and provides various fringe benefits to all employees. The Group reviews its human resources and remuneration policies periodically to ensure that they are in line with market practice and regulatory requirements. As at 30 June 2023, the Group employed the work force of 319 employees, including 192 Chinese employees, 124 New Zealand employees and 3 Australian employees. The total salaries and related costs for the six months ended 30 June 2023 amounted to approximately RMB33.9 million (the first half of 2022: approximately RMB27.9 million).

2023年下半年，全球經濟仍面臨較多不確定性，主要表現在新冠疫情遺留影響依然存在；地緣政治衝突上升；去全球化的趨勢持續增加；某些國家和企業的債務水平過高，可能引發金融風險等。中國作為全球經濟最重要的發展引擎之一，市場看好下半年中國宏觀經濟復甦的韌性和可持續性。

2023年下半年，本集團仍然聚焦於兩大業務板塊，即(i)好健康品牌營養膳食補充劑中國跨境電商和(ii)好健康品牌嬰童系列產品中國線下經銷商渠道。本集團將重點開展：(1)加大中國跨境電商和嬰童系統經銷商渠道宣傳推廣投入的同時，更加關注推廣投入效果和效率(2)加快新產品的研發和推出，滿足目標客戶的需求，增強好健康產品的競爭力，擴大銷售規模(3)改善供應鏈系統管控，提高庫存周轉效率，以此提升本集團整體盈利能力和現金流水平。

### 人力資源管理

高質素及盡責的員工是本集團於競爭市場得以成功不可或缺的資產。藉著定期提供全面的培訓及企業文化教育，本集團員工能夠獲得營養膳食補充劑和母嬰營養品行業方面的持續培訓及發展。此外，本集團為全體僱員提供符合行業慣例並具競爭力的薪酬待遇及多種附帶福利。本集團定期檢討其人力資源及薪酬政策，以確保符合市場慣例及監管規定。於2023年6月30日，本集團僱用319名員工（包括中國192名員工、紐西蘭124名員工及澳大利亞3名員工）。截至2023年6月30日止六個月的薪金及相關成本總額約為人民幣33.9百萬元（2022年上半年：約人民幣27.9百萬元）。

## OTHER INFORMATION 其他資料

### DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at 30 June 2023, the interests and short positions of the Directors, supervisors of the Company (the "Supervisors") and chief executives of the Company in the share capital and underlying shares of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")) as recorded in the register required to be kept under section 352 of the SFO, or as otherwise notified to the Company and The Stock Exchange of Hong Kong Limited (the "Stock Exchange") pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") as set out in Appendix 10 to The Rules Governing the Listing of Securities (the "Listing Rules") on the Stock Exchange, are set out below:

### 董事、監事及高級管理人員於股份及相關股份的權益及淡倉

於2023年6月30日，董事、本公司監事（「監事」）及本公司高級管理人員於本公司或其相聯法團（定義見證券及期貨條例（「證券及期貨條例」）第XV部）股本及相關股份中擁有須記錄於根據證券及期貨條例第352條備存的登記冊的權益及淡倉；或根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）附錄十所載上市發行人董事進行證券交易的標準守則（「標準守則」）須知會本公司及聯交所的權益及淡倉載列如下：

Name	Capacity	Nature of interest	Class of share of the Company	Number of shares held as at 30 June 2023 <sup>(1)</sup> 於2023年6月30日 所持股份數目 <sup>(1)</sup>	Approximate shareholding percentage in the relevant class of shares <sup>(4)</sup> 於相關類別 股份的概約 持股百分比 <sup>(4)</sup> (%)	Approximate shareholding percentage in the total share capital <sup>(3)</sup> 於總 股本的概約 持股百分比 <sup>(3)</sup> (%)
姓名	身份	權益性質	本公司股份類別			
Mr. Gui Pinghu ("Mr. Gui") <sup>(2)</sup> 桂平湖先生 ("桂先生") <sup>(2)</sup>	Director 董事	Beneficial owner 實益擁有人	Domestic Shares 內資股	494,605,108 (L)	73.40%	52.27%
		Interest of spouse 配偶權益	Domestic Shares 內資股	52,965,000 (L)	7.86%	5.60%
		Beneficial owner 實益擁有人	H Shares H股	18,804,000 (L)	6.90%	1.99%
Ms. Zhang Yuan 張源女士	Director 董事	Beneficial owner 實益擁有人	Domestic Shares 內資股	6,599,550 (L)	0.98%	0.70%
		Beneficial owner 實益擁有人	H Shares H股	218,000 (L)	0.08%	0.02%
Ms. Zhu Feifei 朱飛飛女士	Director 董事	Beneficial owner 實益擁有人	Domestic Shares 內資股	659,340 (L)	0.10%	0.07%
Ms. Yu Min 余敏女士	Supervisor 監事	Beneficial owner 實益擁有人	Domestic Shares 內資股	659,340 (L)	0.10%	0.07%



## OTHER INFORMATION 其他資料

### Notes:

- (1) The letter “L” denotes the person’s long position in such securities.
- (2) Mr. Gui is the spouse of Ms. Wu Yanmei. Under the SFO, Mr. Gui was deemed to be interested in the same number of shares in which Ms. Wu Yanmei was interested.
- (3) As at 30 June 2023, the number of total issued shares of the Company was 946,298,370.
- (4) As at 30 June 2023, the number of issued Domestic Shares and H Shares was 673,828,770 and 272,469,600 respectively.

Save as disclosed above, as at 30 June 2023, none of the Directors, Supervisors and chief executives of the Company, or any of their spouses, or children under 18 years of age, has any interests or short positions in the shares and underlying shares of the Company, recorded in the register required to be kept under section 352 of the SFO or required to be notified to the Company and the Stock Exchange pursuant to the Model Code.

### DIRECTORS’ AND SUPERVISORS’ RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save as disclosed under the section headed “Directors’, Supervisors’ and Chief Executives’ Interests and Short Positions in Shares and Underlying Shares”, at no time as at 30 June 2023 was the Company or any of its subsidiaries or fellow subsidiaries a party to any arrangements which enable the Directors and Supervisors to acquire benefits by means of the acquisition of shares in, or debentures of, the Company or any other body corporate, and none of the Directors and Supervisors, or any of their spouses or children under 18 years of age was granted any right to subscribe for the equity or debt securities of the Company or any other body corporate nor had exercised any such right.

### 附註：

- (1) 字母「L」指該人士於該等證券的好倉。
- (2) 桂先生為吳艷梅女士的配偶。根據證券及期貨條例，桂先生被視為擁有吳艷梅女士所持有同等數目股份的權益。
- (3) 於2023年6月30日，本公司之全部已發行股份數目為946,298,370股。
- (4) 於2023年6月30日，已發行內資股及H股數目分別為673,828,770股及272,469,600股。

除上文披露者外，於2023年6月30日，本公司董事、監事及高級管理人員或任何彼等的配偶或未滿18歲的子女，概無於本公司股份及相關股份中擁有任何記錄於須根據證券及期貨條例第352條備存的登記冊或根據標準守則須知會本公司及聯交所的權益或淡倉。

### 董事及監事購買股份或債券的權利

除「董事、監事及高級管理人員於股份及相關股份的權益及淡倉」一節所披露者外，於2023年6月30日任何時間，本公司或其任何附屬公司或同系附屬公司概無訂立任何可使董事及監事通過購買本公司或任何其他法人團體的股份或債券而獲得利益的安排，且概無董事及監事或任何彼等的配偶或未滿18歲的子女獲授予任何權利以認購本公司或任何其他法人團體的股本或債務證券，亦無行使任何該等權利。

## OTHER INFORMATION 其他資料

### SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at 30 June 2023, the interests and short positions of the persons who hold 5% or more of the class shares in the issued share capital of the Company (other than Directors and Supervisors), as recorded in the register required to be kept by the Company under section 336 of the SFO and so far as it was known to Directors are set out below:

### 主要股東於股份及相關股份的權益及淡倉

據董事知悉，於2023年6月30日，按本公司根據證券及期貨條例第336條規定所備存的登記冊所記錄，於本公司已發行股本中持有類別股份5%或以上人士（董事及監事除外）的權益及淡倉載列如下：

Name 姓名／名稱	Nature of interest 權益性質	Class of share of the Company 本公司股份類別	Number of shares held as at 30 June 2023 <sup>(1)</sup> 於2023年6月30日 所持股份數目 <sup>(1)</sup>	Approximate shareholding percentage in the relevant class of shares <sup>(4)</sup> 於相關類別 股份的概約 持股百分比 <sup>(4)</sup> (%)	Approximate shareholding percentage in the total share capital <sup>(3)</sup> 於總 股本的概約 持股百分比 <sup>(3)</sup> (%)
Ms. Wu Yanmei <sup>(2)</sup> 吳艷梅女士 <sup>(2)</sup>	Beneficial owner 實益擁有人	Domestic Shares 內資股	52,965,000 (L)	7.86%	5.60%
	Interest of spouse 配偶權益	Domestic Shares 內資股	494,605,108 (L)	73.40%	52.27%
	Interest of spouse 配偶權益	H Shares H股	18,804,000 (L)	6.90%	1.99%
Ms. Zhou Li 周麗女士	Beneficial owner 實益擁有人	Domestic Shares 內資股	35,075,453 (L)	5.21%	3.71%
Mr. Cheng Xiaowei <sup>(5)</sup> 程小偉先生 <sup>(5)</sup>	Interest of spouse 配偶權益	Domestic Shares 內資股	35,075,453 (L)	5.21%	3.71%
Mr. Gui Ke 桂客先生	Beneficial owner 實益擁有人	Domestic Shares 內資股	61,111,000 (L)	9.07%	6.46%
Ms. Li Shi <sup>(6)</sup> 李詩女士 <sup>(6)</sup>	Interest of spouse 配偶權益	Domestic Shares 內資股	61,111,000 (L)	9.07%	6.46%
Mr. Chen Xuelin 陳學林先生	Beneficial owner 實益擁有人	H Shares H股	27,576,000 (L)	10.12%	2.91%
Hin Sang Group (International) Holding Co. Ltd. 衍生集團(國際)控股有限公司	Beneficial owner 實益擁有人	H Shares H股	59,121,600 (L) <sup>(7)</sup>	21.70%	6.25%
Genwealth Group Holding Company Limited 衍富集團控股有限公司	Interest of controlled corporation 受控法團權益	H Shares H股	59,121,600 (L) <sup>(7)</sup>	21.70%	6.25%
Ms. Kwan Lai Man <sup>(8)</sup> 關麗雯女士 <sup>(8)</sup>	Interest of controlled corporation 受控法團權益	H Shares H股	59,121,600 (L) <sup>(7)</sup>	21.70%	6.25%
	Interest of spouse 配偶權益	H Shares H股	404,000 (L)	0.15%	0.04%
Mr. Pang Siu Hin 彭少衍先生	Interest of controlled corporation 受控法團權益	H Shares H股	59,121,600 (L) <sup>(7)</sup>	21.70%	6.25%
	Beneficial owner 實益擁有人	H Shares H股	404,000 (L)	0.15%	0.04%

## OTHER INFORMATION 其他資料

### Notes:

- (1) The letter "L" represents long position in such securities.
- (2) Ms. Wu Yanmei is the spouse of Mr. Gui. Under the SFO, Ms. Wu Yanmei was deemed to be interested in the same number of shares in which Mr. Gui was interested.
- (3) As at 30 June 2023, the number of total issued shares of the Company was 946,298,370.
- (4) As at 30 June 2023, the number of issued Domestic Shares and H Shares was 673,828,770 and 272,469,600 respectively.
- (5) Mr. Cheng Xiaowei is the spouse of Ms. Zhou Li. Under the SFO, Mr. Cheng Xiaowei was deemed to be interested in the same number of shares in which Ms. Zhou Li was interested.
- (6) Ms. Li Shi is the spouse of Mr. Gui Ke. Under the SFO, Ms. Li Shi was deemed to be interested in the same number of shares in which Mr. Gui Ke was interested.
- (7) These 59,121,600 H Shares were held by Hin Sang Group (International) Holding Co. Ltd., an exempted company incorporated with limited liability in the Cayman Islands whose issued shares are listed on the Stock Exchange (stock code: 6893). Hin Sang Group (International) Holding Co. Ltd. was held as to 50.68% by Genwealth Group Holding Company Limited, which is beneficially owned as to 90% by Mr. Pang Siu Hin and 10% by Ms. Kwan Lai Man. Ms. Kwan Lai Man is the spouse of Mr. Pang Siu Hin. Accordingly, Genwealth Group Holding Company Limited, Mr. Pang Siu Hin and Ms. Kwan Lai Man were deemed to hold interests in these H Shares under the SFO.
- (8) Ms. Kwan Lai Man is the spouse of Mr. Pang Siu Hin. Under the SFO, Ms. Kwan Lai Man was deemed to be interested in the same number of shares in which Mr. Pang Siu Hin was interested.

Save as disclosed above, as at 30 June 2023, the Company had not been notified by any persons (other than Directors, Supervisors or the chief executives of the Company) who had interests or short positions in the shares or underlying shares of the Company which shall be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO and recorded in the register kept by the Company pursuant to section 336 of the SFO.

### 附註：

- (1) 字母「L」指於該等證券的好倉。
- (2) 吳艷梅女士為桂先生的配偶。根據證券及期貨條例，吳艷梅女士將被視為擁有桂先生所持有同等數目股份的權益。
- (3) 於2023年6月30日，本公司之全部已發行股份數目為946,298,370股。
- (4) 於2023年6月30日，已發行內資股及H股數目分別為673,828,770股及272,469,600股。
- (5) 程小偉先生為周麗女士的配偶。根據證券及期貨條例，程小偉先生被視為擁有周麗女士所持有同等數目股份的權益。
- (6) 李詩女士為桂客先生的配偶。根據證券及期貨條例，李詩女士將被視為擁有桂客先生所持有同等數目股份的權益。
- (7) 該等59,121,600股H股由衍生集團(國際)控股有限公司(一間於開曼群島註冊成立的獲豁免有限公司，其已發行股份於聯交所上市(股份代號：6893))持有。衍生集團(國際)控股有限公司由衍富集團控股有限公司持有50.68%，其分別由彭少衍先生及關麗雯女士實益擁有90%及10%權益。關麗雯女士為彭少衍先生的配偶。因此，根據證券及期貨條例，衍富集團控股有限公司、彭少衍先生及關麗雯女士被視為於該等H股中持有權益。
- (8) 關麗雯女士為彭少衍先生之配偶。根據證券及期貨條例，關麗雯女士被視為於彭少衍先生擁有權益的相同股份數目中擁有權益。

除上文披露者外，於2023年6月30日，本公司概無獲任何人士(董事、監事或本公司高級管理人員除外)告知彼於本公司股份或相關股份中擁有須根據證券及期貨條例第XV部第2及3分部規定向本公司披露及根據證券及期貨條例第336條規定記錄於本公司備存的登記冊的權益或淡倉。



## OTHER INFORMATION 其他資料

### PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

For the six months ended 30 June 2023, neither the Company nor any of its subsidiaries has purchased, redeemed or sold any of the Company's listed securities.

### DISCLOSURE OF INFORMATION OF DIRECTORS AND SUPERVISORS UNDER RULE 13.51B(1) OF THE LISTING RULES

Pursuant to Rule 13.51B(1) of the Listing Rules, there were no changes in Directors' and Supervisors information since the date of publication of the Company's 2022 annual report.

### MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as set out in Appendix 10 to the Listing Rules on the Stock Exchange as the code of conduct for Directors in their dealings in the Company's securities.

The Company has made specific enquiry with the Directors and Supervisors and all the Directors and Supervisors confirmed that they have complied with the Model Code throughout the six months ended 30 June 2023 and up to the date of this interim report.

### CODE OF CORPORATE GOVERNANCE PRACTICE

The Company's corporate governance practices are based on the principles and code provisions as set out in the Corporate Governance Code (the "CG Code") contained in Appendix 14 to the Listing Rules on the Stock Exchange.

In the opinion of the Directors, the Company has complied with Part 2 of the code provisions as set out in the CG Code contained in Appendix 14 to the Listing Rules for the six months ended 30 June 2023 and up to the date of this interim report.

### 購買、出售或贖回本公司上市證券

截至2023年6月30日止六個月，本公司或其任何附屬公司概無購買、贖回或出售本公司的任何上市證券。

### 董事及監事於上市規則第13.51B(1)條項下之披露資料

根據上市規則第13.51B(1)條，自本公司2022年年報刊發日期以來，董事及監事資料概無變動。

### 證券交易的標準守則

本公司已採納聯交所上市規則附錄十所載的標準守則，作為規管董事買賣本公司證券的行為守則。

本公司已向董事及監事作出特定查詢，且全體董事及監事已確認，彼等於截至2023年6月30日止六個月及直至本中期報告日期均已遵守標準守則。

### 企業管治常規守則

本公司的企業管治常規乃基於聯交所上市規則附錄十四所載企業管治守則(「企業管治守則」)載列的原則及守則條文。

董事認為，本公司截至2023年6月30日止六個月及直至本中期報告日期均已遵守上市規則附錄十四所載的企業管治守則載列的守則條文第二部分。

### MATERIAL INVESTMENTS, ACQUISITIONS AND DISPOSALS

During the six months ended 30 June 2023, there were no material investments, acquisitions or disposals of subsidiaries, associated companies or joint ventures.

### EVENTS SUBSEQUENT TO THE SIX MONTHS ENDED 30 JUNE 2023

Subsequent to the six months ended 30 June 2023 and up to the date of this interim report, there were no significant events affecting the Group.

### INTERIM DIVIDEND

The Board has resolved not to declare any interim dividend for the six months ended 30 June 2023 (For the six months ended 30 June 2022: Nil).

### AUDIT COMMITTEE

The unaudited condensed consolidated interim results of the Group for the six months ended 30 June 2023 have been reviewed by the audit committee of the Company (the “**Audit Committee**”). The Audit Committee has been established in compliance with the Listing Rules with written terms of reference in compliance with the CG Code. The Audit Committee consists of three independent non-executive Directors, namely Mr. Yu Bo, Ms. Cai Tianchen and Mr. Wang Wei. Ms. Cai Tianchen serves as the chairman of the Audit Committee. The primary responsibilities of the Audit Committee are to review and monitor the financial reporting, internal control and risk management systems of the Company and to assist the Board to fulfill its responsibilities over audit.

### 重大投資、收購及出售

截至2023年6月30日止六個月，概無對附屬公司、聯營公司或合營企業進行重大投資、收購或出售。

### 截至2023年6月30日止六個月後事項

於截至2023年6月30日止六個月後及直至本中期報告日期，並無發生對本集團造成影響的重大事項。

### 中期股息

董事會已決議不派付截至2023年6月30日止六個月之任何中期股息(截至2022年6月30日止六個月：無)。

### 審核委員會

本集團截至2023年6月30日止六個月的未經審核簡明綜合中期業績已由本公司審核委員會(「**審核委員會**」)審閱。審核委員會已遵照上市規則成立，並制定符合企業管治守則的書面職權範圍。審核委員會由三名獨立非執行董事余波先生、蔡天晨女士及王瑋先生組成。蔡天晨女士為審核委員會主席。審核委員會的主要職責為審閱及監察本公司的財務申報、內部控制及風險管理系統，以及協助董事會履行其審核職責。

# INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

## 中期簡明綜合損益及其他全面收益表

For the six months ended 30 June 2023 截至2023年6月30日止六個月

For the six months ended 30 June  
截至6月30日止六個月

		Notes 附註	2023 2023年 RMB'000 人民幣千元 (unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (unaudited) (未經審核)
<b>REVENUE</b>	<b>收益</b>	4	<b>218,930</b>	122,760
Cost of sales	銷售成本		<b>(73,063)</b>	(51,077)
<b>Gross profit</b>	<b>毛利</b>		<b>145,867</b>	71,683
Other income and gains	其他收入及盈利	4	<b>3,805</b>	3,133
Selling and distribution expenses	銷售及經銷開支		<b>(85,063)</b>	(46,208)
Administrative expenses	行政開支		<b>(30,596)</b>	(29,571)
Finance costs	融資成本		<b>(1,642)</b>	(252)
Other expenses	其他開支		<b>(2,516)</b>	(3,113)
Profit/(Loss) before tax	除稅前溢利/(虧損)	5	<b>29,855</b>	(4,328)
Income tax expense	所得稅開支	6	<b>(2,033)</b>	(856)
<b>Profit/(Loss) for the period</b>	<b>期間溢利/(虧損)</b>		<b>27,822</b>	(5,184)
Profit/(Loss) attributable to: Owners of the parent	以下各項應佔溢利/(虧損): 母公司擁有人		<b>27,822</b>	(5,184)
<b>Other comprehensive income/(loss)</b>	<b>其他全面收益/(虧損)</b>			
<b>Other comprehensive income that will not be reclassified to profit or loss in subsequent periods, net of tax</b>	<b>於期後將不會重新分類為利潤或虧損的其他全面收益，除稅後</b>			
Gains on property revaluation	物業重估收益		-	6,755
<b>Other comprehensive loss that may be reclassified to profit or loss in subsequent periods, net of tax</b>	<b>於期後可能重新分類為利潤或虧損的其他全面虧損，除稅後</b>			
Exchange differences on translation of foreign operations	換算海外業務的匯兌差額		<b>(382)</b>	(3,287)
<b>Other comprehensive income/(loss) for the period</b>	<b>期間其他全面收益/(虧損)</b>		<b>(382)</b>	3,468
<b>Total comprehensive income/(loss) for the period</b>	<b>期間全面收益/(虧損)總額</b>		<b>27,440</b>	(1,716)
Total comprehensive income/(loss) attributable to: Owners of the parent	以下各項應佔全面收益/(虧損)總額: 母公司擁有人		<b>27,440</b>	(1,716)
<b>Earnings/(Loss) per share attributable to ordinary equity holders of the parent:</b>	<b>母公司普通權益持有人應佔每股盈利/(虧損):</b>		<b>RMB 人民幣</b>	RMB 人民幣
— Basic and diluted for earnings/(loss)	— 基本及攤薄盈利/(虧損)	8	<b>2.94 cents 分</b>	(0.55) cent 分



# INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

## 中期簡明綜合財務狀況表

As at 30 June 2023 於 2023 年 6 月 30 日

		Notes 附註	30 June 2023 2023 年 6 月 30 日 RMB'000 人民幣千元 (unaudited) (未經審核)	31 December 2022 2022 年 12 月 31 日 RMB'000 人民幣千元 (audited) (經審核)
<b>Non-current assets</b>	<b>非流動資產</b>			
Property, plant and equipment	物業、廠房及設備	9	76,594	80,074
Investment properties	投資物業		72,267	72,954
Right-of-use assets	使用權資產		38,276	39,985
Goodwill	商譽		32,257	32,374
Other intangible assets	其他無形資產		4,033	5,077
Deferred tax assets	遞延稅項資產		11,995	12,125
Total non-current assets	非流動資產總額		235,422	242,589
<b>Current assets</b>	<b>流動資產</b>			
Inventories	存貨	10	114,037	75,272
Trade receivables	貿易應收款項	11	32,024	28,184
Prepayments, deposits and other receivables	預付款項、按金及 其他應收款項	12	17,984	16,070
Tax recoverable	可收回稅項		-	131
Restricted cash	受限制現金		-	1,350
Cash and cash equivalents	現金及現金等價物	13	60,786	73,391
Total current assets	流動資產總額		224,831	194,398
<b>TOTAL ASSETS</b>	<b>資產總值</b>		<b>460,253</b>	436,987
<b>Current liabilities</b>	<b>流動負債</b>			
Trade payables	貿易應付款項	14	31,835	21,528
Other payables and accruals	其他應付款項及應計費用	15	25,522	41,101
Lease liabilities	租賃負債		4,263	4,368
Tax payable	應付稅項		2,228	-
Total current liabilities	流動負債總額		63,848	66,997
<b>NET CURRENT ASSETS</b>	<b>流動資產淨值</b>		<b>160,983</b>	127,401
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>	<b>總資產減流動負債</b>		<b>396,405</b>	369,990
<b>NON-CURRENT LIABILITIES</b>	<b>非流動負債</b>			
Lease liabilities	租賃負債		30,756	31,385
Deferred tax liabilities	遞延稅項負債		13,628	14,031
Provision	撥備		781	774
Total non-current liabilities	非流動負債總額		45,165	46,190
<b>NET ASSETS</b>	<b>資產淨值</b>		<b>351,240</b>	323,800
<b>EQUITY</b>	<b>權益</b>			
<b>Equity attributable to owners of the parent</b>	<b>母公司擁有人應佔權益</b>			
Share capital	股本	16	94,630	94,630
Other Reserves	其他儲備		256,610	229,170
<b>TOTAL EQUITY</b>	<b>權益總值</b>		<b>351,240</b>	323,800

# INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

## 中期簡明綜合權益變動表

For the six months ended 30 June 2023 截至2023年6月30日止六個月

		Attributable to owners of the parent 母公司擁有人應佔								
		Share capital	Capital reserve	Exchange fluctuation reserve	Statutory surplus reserve	Merger reserve	Other reserve	Asset revaluation reserve	Accumulated losses	Total equity
		股本	資本儲備	匯兌波動儲備	法定盈餘儲備	合併儲備	其他儲備	資產重估儲備	累計虧損	總權益
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
		(note 16)								
		(附註16)								
At 1 January 2023 (audited)	於2023年1月1日(經審核)	94,630	544,223*	(6,333)*	55,902*	(3,871)*	(2,022)*	12,972*	(371,701)*	323,800
Profit for the period	期間溢利	-	-	-	-	-	-	-	27,822	27,822
Exchange differences on translation of foreign operations	換算海外業務的匯兌差額	-	-	(382)	-	-	-	-	-	(382)
Total comprehensive income/(loss) for the period	期間全面收益/(虧損)總額	-	-	(382)	-	-	-	-	27,822	27,440
At 30 June 2023 (unaudited)	於2023年6月30日(未經審核)	94,630	544,223*	(6,715)*	55,902*	(3,871)*	(2,022)*	12,972*	(343,879)*	351,240

\* These reserve accounts comprise the consolidated other reserves of RMB256,610,000 (2022: RMB229,170,000) in the consolidated statement of financial position.

\* 此等儲備賬目包括綜合財務狀況表內的綜合其他儲備人民幣256,610,000元(2022年: 人民幣229,170,000元)。

		Attributable to owners of the parent 母公司擁有人應佔								
		Share capital	Capital reserve	Exchange fluctuation reserve	Statutory surplus reserve	Merger reserve	Other reserve	Asset revaluation reserve	Accumulated losses	Total equity
		股本	資本儲備	匯兌波動儲備	法定盈餘儲備	合併儲備	其他儲備	資產重估儲備	累計虧損	總權益
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
		(note 16)								
		(附註16)								
At 1 January 2022 (audited)	於2022年1月1日(經審核)	94,630	544,223	(7,380)	55,902	(3,871)	(2,022)	6,217	(357,455)	330,244
Loss for the period	期間虧損	-	-	-	-	-	-	-	(5,184)	(5,184)
Changes in fair value of investment properties, net of tax	投資物業公允價值變動, 除稅後	-	-	-	-	-	-	6,755	-	6,755
Exchange differences on translation of foreign operations	換算海外業務的匯兌差額	-	-	(3,287)	-	-	-	-	-	(3,287)
Total comprehensive income/(loss) for the period	期間全面收益/(虧損)總額	-	-	(3,287)	-	-	-	6,755	(5,184)	(1,716)
At 30 June 2022 (unaudited)	於2022年6月30日(未經審核)	94,630	544,223*	(10,667)*	55,902*	(3,871)*	(2,022)*	12,972*	(362,639)*	328,528

# INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

## 中期簡明綜合現金流量表

For the six months ended 30 June 2023 截至2023年6月30日止六個月

		For the six months ended 30 June 截至6月30日止六個月	
		2023 2023年 RMB'000 人民幣千元 (unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (unaudited) (未經審核)
	Note 附註		
Net cash used in operating activities	經營活動所用現金淨額	<b>(10,125)</b>	(6,199)
Net cash used in investing activities	投資活動所用現金淨額	<b>(493)</b>	(1,483)
Net cash used in financing activities	融資活動所用現金淨額	<b>(2,211)</b>	(2,096)
Net decrease in cash and cash equivalents	現金及現金等價物減少淨額	<b>(12,829)</b>	(9,778)
Cash and cash equivalents at beginning of the period	期初現金及現金等價物	<b>73,391</b>	72,057
Effect of exchange rate changes, net	匯率變動的影響，淨額	<b>224</b>	(548)
Cash and cash equivalents at end of the period	期末現金及現金等價物	<b>60,786</b>	61,731



# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 1. CORPORATE AND GROUP INFORMATION

The Company is a joint stock limited liability company established in the People's Republic of China (the "PRC"). The address of its registered office is 4/F, Building 3, 3 Qingma Road, Qixia District, Nanjing, Jiangsu Province, the PRC.

The Group is principally engaged in the manufacturing and sale of nutritional supplements and health food products in the PRC, Australia and New Zealand.

#### Information about subsidiaries

Particulars of the Company's subsidiaries as at 30 June 2023 are as follows:

### 1. 公司及集團資料

本公司乃於中華人民共和國（「中國」）成立的股份有限公司。註冊辦事處地址為中國江蘇省南京市栖霞區青馬路3號3號樓4樓。

本集團主要在中國、澳大利亞及紐西蘭從事製造及銷售營養膳食補充劑及保健食品。

#### 有關附屬公司之資料

本公司附屬公司於2023年6月30日之詳情如下：

Name 名稱	Place of incorporation or establishment and place of operation/ date of incorporation and establishment/ type of legal entity 註冊成立或成立地點及經營地點/ 註冊成立及成立日期/法人類別	Fully paid share capital/ registered capital 已繳足股本/ 註冊資本	Percentage of equity attributable to the Company		Principal activities 主要業務
			Direct 直接	Indirect 間接	
南京中生生物科技有限公司	The PRC 17 June 2003 Limited liability company  中國 2003年6月17日 有限公司	RMB50,000,000  人民幣 50,000,000元	100%	–	Manufacture, processing and sale of health food products; industrial property leasing 生產、加工及銷售保健食品；工業物業租賃
紐好健康營養(南京)有限公司	The PRC 6 May 2021 Limited liability company  中國 2021年5月6日 有限公司	RMB1,000,000  人民幣 1,000,000元	100%	–	Trading of food products 食品貿易

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 1. CORPORATE AND GROUP INFORMATION (CONTINUED)

#### Information about subsidiaries (Continued)

### 1. 公司及集團資料(續)

#### 有關附屬公司之資料(續)

Name 名稱	Place of incorporation or establishment and place of operation/ date of incorporation and establishment/ type of legal entity 註冊成立或成立地點及經營地點/ 註冊成立及成立日期/法人類別	Fully paid share capital/ registered capital 已繳足股本/ 註冊資本	Percentage of equity attributable to the Company 本公司應佔權益之百分比		Principal activities 主要業務
			Direct 直接	Indirect 間接	
Australia Cobayer Health Food Co Pty Ltd.	Australia 2 March 2009 Limited liability company 澳大利亞 2009年3月2日 有限公司	AUD2,000  澳元2,000	100%	-	Trading of food products  食品貿易
上海惟翊投資管理有限公司	The PRC 21 October 2014 Limited liability company 中國 2014年10月21日 有限公司	RMB120,000,000  人民幣 120,000,000元	100%	-	Investment holding  投資控股
Good Health Products Limited	New Zealand 22 December 1987 Limited liability company 紐西蘭 1987年12月22日 有限公司	NZD2,200,002  紐西蘭元 2,200,002	-	100%	Manufacture, processing and sale of health food products 生產、加工及銷售保健食品
Living Nature Natural Products Limited	New Zealand 1987 Limited liability company 紐西蘭 1987年 有限公司	NZD14,784,444  紐西蘭元 14,784,444	100%	-	Manufacture, and sale of cosmetics and skin care products 生產及銷售化妝品及護膚品

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 2. BASIS OF PREPARATION AND CHANGES TO THE GROUP'S ACCOUNTING POLICIES

#### 2.1 Basis of preparation

These unaudited interim condensed consolidated financial statements of the Group for the six months ended 30 June 2023 (the "period") have been prepared in accordance with Hong Kong Accounting Standards ("HKAS") 34 *Interim Financial Reporting*.

These unaudited interim condensed consolidated financial statements are presented in Renminbi ("RMB") and all values are rounded to the nearest thousand except when otherwise indicated.

These unaudited interim condensed consolidated financial statements do not include all information and disclosures required in the Group's annual consolidated financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2022.

#### 2.2 Changes in accounting policies and disclosures

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2022, except for the adoption of the following new and revised Hong Kong Financial Reporting Standards ("HKFRSs") for the first time for the current period's financial information.

HKFRS 17	<i>Insurance Contracts</i>
Amendments to HKFRS 17	<i>Insurance Contracts</i>
Amendment to HKFRS 17	<i>Initial Application of HKFRS 17 and HKFRS 9 — Comparative Information</i>
Amendments to HKAS 1 and HKFRS Practice Statement 2	<i>Disclosure of Accounting Policies</i>
Amendments to HKAS 8	<i>Definition of Accounting Estimates</i>
Amendments to HKAS 12	<i>Deferred Tax related to Assets and Liabilities arising from a Single Transaction</i>
Amendments to HKAS 12	<i>International Tax Reform — Pillar Two Model Rules</i>

### 2. 編製基準及本集團會計政策變動

#### 2.1 編製基準

本集團截至2023年6月30日止六個月(「本期」)的此等未經審核中期簡明綜合財務報表乃根據香港會計準則(「香港會計準則」)第34號*中期財務報告*而編製。

此等未經審核中期簡明綜合財務報表乃以人民幣(「人民幣」)呈列，而除非另有指明外，所有數值已約整至最接近的千位。

此等未經審核中期簡明綜合財務報表並未包含本集團年度綜合財務報表須載入的所有資料及披露，且應與本集團截至2022年12月31日止年度的年度綜合財務報表一併閱讀。

#### 2.2 會計政策變動及披露

編製中期簡明綜合財務資料所採用的會計政策與編製本集團截至2022年12月31日止年度的年度綜合財務報表所採用者一致，惟於本期財務資料首次採用以下新訂及經修訂的香港財務報告準則(「香港財務報告準則」)除外。

香港財務報告準則第17號	保險合約
香港財務報告準則第17號修訂本	保險合約
香港財務報告準則第17號修訂本	香港財務報告準則第17號及香港財務報告準則第9號的初步應用—可比較資料
香港會計準則第1號及香港財務報告準則實務公告第2號修訂本	會計政策披露
香港會計準則第8號修訂本	會計估計之定義
香港會計準則第12號修訂本	與單一交易產生之資產及負債相關之遞延稅項
香港會計準則第12號修訂本	國際稅務改革—支柱二示範規則



# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

## 2. BASIS OF PREPARATION AND CHANGES TO THE GROUP'S ACCOUNTING POLICIES (CONTINUED)

### 2.2 Changes in accounting policies and disclosures (Continued)

The nature and impact of the new and revised HKFRSs that are applicable to the Group are described below:

- (a) Amendments to HKAS 1 require entities to disclose their material accounting policy information rather than their significant accounting policies. Accounting policy information is material if, when considered together with other information included in an entity's financial statements, it can reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements. Amendments to HKFRS Practice Statement 2 provide non-mandatory guidance on how to apply the concept of materiality to accounting policy disclosures. The Group has applied the amendments since 1 January 2023. The amendments did not have any impact on the Group's interim condensed consolidated financial information but are expected to affect the accounting policy disclosures in the Group's annual consolidated financial statements.
- (b) Amendments to HKAS 8 clarify the distinction between changes in accounting estimates and changes in accounting policies. Accounting estimates are defined as monetary amounts in financial statements that are subject to measurement uncertainty. The amendments also clarify how entities use measurement techniques and inputs to develop accounting estimates. The Group has applied the amendments to changes in accounting policies and changes in accounting estimates that occur on or after 1 January 2023. Since the Group's policy of determining accounting estimates aligns with the amendments, the amendments did not have any impact on the financial position or performance of the Group.

## 2. 編製基準及本集團會計政策變動(續)

### 2.2 會計政策變動及披露(續)

適用於本集團的新訂及經修訂香港財務報告準則的性質及影響概述如下：

- (a) 香港會計準則第1號修訂本要求實體披露其重大會計政策資料，而非其主要會計政策。倘連同實體財務報表所載其他資料一併考慮，會計政策資料可以合理預期會影響通用財務報表的主要使用者根據該等財務報表所作出的決定，則該會計政策資料屬重大。香港財務報告準則實務報告第2號之修訂本就重要性概念應用於會計政策披露之方式提供非強制性指引。本集團自2023年1月1日起應用該等修訂本。該等修訂本對本集團中期簡明綜合財務資料並無任何影響，但預計將影響本集團年度綜合財務報表中的會計政策披露。
- (b) 香港會計準則第8號修訂本澄清會計估算變動與會計政策變動之間的區別。會計估算界定為受到計量不確定性規限的財務報表所載貨幣金額。該等修訂本亦澄清實體如何運用計量技巧及輸入數據來制定會計估算。本集團將該等修訂本應用於2023年1月1日或之後發生的會計政策變動及會計估算變動。由於本集團確定會計估算的政策與該等修訂本一致，該等修訂本並無對本集團的財務狀況或表現產生任何影響。

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 2. BASIS OF PREPARATION AND CHANGES TO THE GROUP'S ACCOUNTING POLICIES (CONTINUED)

#### 2.2 Changes in accounting policies and disclosures (Continued)

The nature and impact of the new and revised HKFRSs that are applicable to the Group are described below: (Continued)

- (c) Amendments to HKAS 12 *Deferred Tax related to Assets and Liabilities arising from a Single Transaction* narrow the scope of the initial recognition exception in HKAS 12 so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences, such as leases and decommissioning obligations. Therefore, entities are required to recognise a deferred tax asset (provided that sufficient taxable profit is available) and a deferred tax liability for temporary differences arising from these transactions. The Group has applied the amendments on temporary differences related to leases and decommissioning obligations as at 1 January 2022, with any cumulative effect recognised as an adjustment to the balance of retained profits or other component of equity as appropriate at that date. In addition, the Group has applied the amendments prospectively to transactions other than leases and decommissioning obligations that occurred on or after 1 January 2022, if any. The amendments did not have any impact on the Group's interim condensed consolidated financial information.

### 2. 編製基準及本集團會計政策變動 (續)

#### 2.2 會計政策變動及披露 (續)

適用於本集團的新訂及經修訂香港財務報告準則的性質及影響概述如下：(續)

- (c) 香港會計準則第12號修訂本與單一交易產生之資產及負債相關之遞延稅項收窄初步確認豁免香港會計準則第12號的範圍，使有關豁免不再適用於導致應課稅項與可扣減暫時差額相同的交易，例如租賃及除役責任。因此，實體須就該等交易所產生的暫時差額確認遞延稅項資產(惟有足夠應課稅溢利)及遞延稅項負債。本集團已於2022年1月1日將該等修訂本應用於與租賃及除役責任相關的暫時差額，任何累計影響均確認為對該日保留利潤或其他權益組成部分(如適用)結餘的調整。此外，本集團已前瞻性地將該等修訂本應用於2022年1月1日或之後發生的租賃及除役責任以外的交易(如有)。該等修訂本對本集團中期簡明綜合財務資料並無任何影響。

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 2. BASIS OF PREPARATION AND CHANGES TO THE GROUP'S ACCOUNTING POLICIES (CONTINUED)

#### 2.2 Changes in accounting policies and disclosures (Continued)

The nature and impact of the new and revised HKFRSs that are applicable to the Group are described below: (Continued)

- (d) Amendments to HKAS 12 *International Tax Reform — Pillar Two Model Rules* introduce a mandatory temporary exception from the recognition and disclosure of deferred taxes arising from the implementation of the Pillar Two model rules published by the Organisation for Economic Co-operation and Development. The amendments also introduce disclosure requirements for the affected entities to help users of the financial statements better understand the entities' exposure to Pillar Two income taxes, including the disclosure of current tax related to Pillar Two income taxes separately in the periods when Pillar Two legislation is effective and the disclosure of known or reasonably estimable information of their exposure to Pillar Two income taxes in periods in which the legislation is enacted or substantively enacted but not yet in effect. Entities are required to disclose the information relating to their exposure to Pillar Two income taxes in annual periods beginning on or after 1 January 2023, but are not required to disclose such information for any interim periods ending on or before 31 December 2023. The Group has applied the amendments retrospectively. Since the Group did not fall within the scope of the Pillar Two model rules, the amendments did not have any impact to the Group.

### 3. OPERATING SEGMENT INFORMATION

#### (a) Reportable segments

The Group determines its operating segments based on the reports reviewed by the chief operating decision maker that are used to make strategic decisions. For management purposes, the Group operates in one business unit based on its products, and has one reportable segment which is the manufacture and sale of nutritional supplements and the sale of packaged health food products in the People's Republic of China (the "PRC"), Australia and New Zealand.

### 2. 編製基準及本集團會計政策變動 (續)

#### 2.2 會計政策變動及披露 (續)

適用於本集團的新訂及經修訂香港財務報告準則的性質及影響概述如下：(續)

- (d) 香港會計準則第12號的修訂本《國際稅務改革 — 支柱二示範規則》引入強制性暫時豁免因實施經濟合作與發展組織發佈的支柱二示範規則產生的遞延稅項的確認及披露。該等修訂本亦引入受影響實體的披露規定，以幫助財務報表的使用者更好地了解實體支柱二所得稅的風險，包括在支柱二立法生效期間單獨披露與支柱二所得稅有關的即期稅項，及在立法已頒佈或實質上已頒佈但尚未生效期間披露已知或合理可估計的支柱二所得稅風險的資料。實體須於2023年1月1日或之後開始的年度期間披露有關其支柱二所得稅風險的資料，但毋須披露截至2023年12月31日或之前的任何中期期間的有關資料。本集團已追溯應用該等修訂本。由於本集團並不屬於支柱二示範規則的範圍，故該等修訂本對本集團並無任何影響。

### 3. 經營分部資料

#### (a) 可報告分部

本集團根據由主要經營決策人審閱用於作出戰略決策的報告釐定其經營分部。就管理方面而言，本集團經營以其產品為單位的單一業務，並設有單一可報告分部，即在中華人民共和國（「中國」）、澳大利亞及紐西蘭製造及銷售營養膳食補充劑以及銷售包裝保健食品。



# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 3. OPERATING SEGMENT INFORMATION (CONTINUED)

#### (b) Geographical information

Most of the group companies are domiciled in the PRC and the majority of the non-current assets are located in the PRC, New Zealand and Australia. The Group's revenue from external customers is primarily derived in the PRC, New Zealand and Australia.

The following is an analysis of the Group's revenue from its major markets:

		For the Six months ended 30 June 截至6月30日止六個月	
		2023 2023年 RMB'000 人民幣千元 (unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (unaudited) (未經審核)
Mainland China	中國內地	159,917	75,937
New Zealand	紐西蘭	50,411	40,264
Australia	澳大利亞	2,556	828
Other countries	其他國家	6,046	5,731
		<b>218,930</b>	122,760

#### (c) Non-current assets

		30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (audited) (經審核)
Mainland China	中國內地	147,652	150,933
New Zealand	紐西蘭	42,444	45,800
Australia	澳大利亞	1,074	1,357
		<b>191,170</b>	198,090

The non-current assets information above is based on the locations of the assets and excludes goodwill and deferred tax assets.

#### (d) Information about major customers

No revenue from transactions with a single external customer amounted to 10% or more of the Group's revenue.

### 3. 經營分部資料(續)

#### (b) 地區資料

本集團旗下大部份公司的所屬地為中國且大部份非流動資產均位於中國、紐西蘭及澳大利亞。本集團來自外部客戶的收益主要在中國、紐西蘭及澳大利亞產生。

以下為本集團來自主要市場的收益分析：

		For the Six months ended 30 June 截至6月30日止六個月	
		2023 2023年 RMB'000 人民幣千元 (unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (unaudited) (未經審核)
Mainland China	中國內地	159,917	75,937
New Zealand	紐西蘭	50,411	40,264
Australia	澳大利亞	2,556	828
Other countries	其他國家	6,046	5,731
		<b>218,930</b>	122,760

#### (c) 非流動資產

		30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (audited) (經審核)
Mainland China	中國內地	147,652	150,933
New Zealand	紐西蘭	42,444	45,800
Australia	澳大利亞	1,074	1,357
		<b>191,170</b>	198,090

以上非流動資產之資料乃基於資產所處位置且未計及商譽及遞延稅項資產。

#### (d) 有關主要客戶的資料

概無與單一外部客戶交易的收益佔本集團收益的10%或以上。

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 4. REVENUE, OTHER INCOME AND GAINS

Revenue represents the net invoiced value of goods sold, after allowances for returns and trade discounts, and the value of services rendered.

An analysis of revenue, other income and gains is as follows:

### 4. 收益、其他收入及盈利

收益指已售貨品經扣除退貨及貿易折扣後的發票淨值及所提供服務的價值。

收益、其他收入及盈利的分析如下：

		For the Six months ended 30 June 截至6月30日止六個月	
		2023 2023年 RMB'000 人民幣千元 (unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (unaudited) (未經審核)
<b>Type of goods or services</b>	<b>貨品或服務類型</b>		
Sale of industrial products	銷售工業產品	218,930	122,760
		<b>218,930</b>	122,760
<b>Timing of revenue recognition</b>	<b>收益確認時間</b>		
Goods or services transferred at a point in time	按轉讓貨品或服務時的時間點	218,930	122,760
Total revenue from contracts with customers	來自客戶合約的收益總額	<b>218,930</b>	122,760

		For the Six months ended 30 June 截至6月30日止六個月	
		2023 2023年 RMB'000 人民幣千元 (unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (unaudited) (未經審核)
<b>Other income and gains</b>	<b>其他收入及盈利</b>		
Bank interest income	銀行利息收入	386	284
Government grants	政府補助金	644	278
Gain on disposal of a subsidiary	出售一間附屬公司的收益	61	-
Rental income	租金收入	2,458	2,215
Other	其他	256	356
		<b>3,805</b>	3,133

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 5. PROFIT/(LOSS) BEFORE TAX

Profit/(Loss) before tax is arrived at after charging/(crediting):

### 5. 除稅前溢利／(虧損)

除稅前溢利／(虧損)乃在扣除／(計入)以下各項後得出：

		For the Six months ended 30 June 截至6月30日止六個月	
		2023 2023年 RMB'000 人民幣千元 (unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (unaudited) (未經審核)
Cost of inventories sold	已售存貨的成本	73,063	51,077
Staff costs (excluding compensation of key management personnel of the Group)	員工成本(不包括本集團主要管理人員薪酬)	29,612	24,490
Depreciation of right-of-use assets	使用權資產折舊	1,553	1,805
Amortisation of intangible assets	無形資產攤銷	998	1,014
Depreciation of property, plant and equipment	物業、廠房及設備折舊	4,400	5,024
Lease payments not included in the measurement of lease liabilities	並未計入租賃負債計量的租賃付款	469	94
Impairment of trade receivables	貿易應收款項減值	392	217
Exchange differences, net	匯兌差額淨額	983	2,483
Government grants	政府補助金	(644)	(278)
Gain on disposal of a subsidiary	出售一間附屬公司的收益	(61)	–
Research and development expenses	研發開支	355	457



# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 6. INCOME TAX EXPENSE

The amounts of income tax expense in the interim condensed consolidated statement of profit or loss and other comprehensive income represent:

		For the Six months ended 30 June 截至6月30日止六個月	
		2023 2023年 RMB'000 人民幣千元 (unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (unaudited) (未經審核)
Current tax	即期稅項	2,307	-
Deferred tax	遞延稅項	(274)	856
Total tax expense for the period	本期稅項開支總額	2,033	856

The income tax of the Company and its subsidiaries established in the PRC are subject to the statutory rate of 25% of the assessable profits as determined in accordance with the relevant income tax rules and regulations of the PRC. New Zealand Income tax is calculated at 28% of the assessable profits of the subsidiaries operating in New Zealand. Australia Income tax is calculated at 30% of the assessable profits of the subsidiary operating in Australia.

### 7. DIVIDEND

The board has resolved not to declare any interim dividend in respect of the six months ended 30 June 2023 (six months ended 30 June 2022: Nil).

No proposed dividend declared by the board for the year ended 31 December 2022.

### 6. 所得稅開支

於中期簡明綜合損益及其他全面收益表中的所得稅開支金額為：

		For the Six months ended 30 June 截至6月30日止六個月	
		2023 2023年 RMB'000 人民幣千元 (unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (unaudited) (未經審核)
Current tax	即期稅項	2,307	-
Deferred tax	遞延稅項	(274)	856
Total tax expense for the period	本期稅項開支總額	2,033	856

本公司及其於中國成立的附屬公司的所得稅須按根據中國相關所得稅規則及規例釐定的應課稅利潤25%的法定稅率繳納。紐西蘭所得稅按於紐西蘭營運的附屬公司應課稅利潤的28%計算。澳大利亞所得稅按於澳大利亞營運的附屬公司應課稅利潤的30%計算。

### 7. 股息

董事會已決議不就截至2023年6月30日止六個月宣派任何中期股息(截至2022年6月30日止六個月：無)。

董事會並無建議宣派截至2022年12月31日止年度之任何股息。

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 8. EARNINGS/(LOSS) PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings/(loss) per share amounts is based on the profit/(loss) for the period attributable to ordinary equity holders of the parent and the weighted average number of ordinary shares of 946,298,370 (2022: 946,298,370) in issue during the period, as adjusted to reflect the rights issue during the period.

The Group had no potentially dilutive ordinary shares in issue during the periods ended 30 June 2023 and 2022.

The calculation of basic earnings/(loss) per share is based on:

### 8. 母公司普通權益持有人應佔每股盈利/(虧損)

每股基本盈利/(虧損)乃按母公司普通權益持有人應佔本期溢利/(虧損)及本期內已發行普通股加權平均數946,298,370股(2022年: 946,298,370股)計算,並作出調整以反映期內進行的供股。

截至2023年及2022年6月30日止期間,本集團並無潛在攤薄已發行普通股。

每股基本盈利/(虧損)乃按以下各項計算:

		For the Six months ended 30 June 截至6月30日止六個月	
		2023 2023年 RMB'000 人民幣千元 (unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (unaudited) (未經審核)
<b>Earnings/(Loss)</b>	<b>盈利/(虧損)</b>		
Profit/(Loss) attributable to ordinary equity holders of the parent, used in the basic loss per share calculation	母公司普通權益持有人應佔溢利/(虧損), 用於計算每股基本虧損	<b>27,822</b>	(5,184)
		<b>30 June 2023 2023年 6月30日 (unaudited) (未經審核)</b>	30 June 2022 2022年 6月30日 (unaudited) (未經審核)
<b>Shares</b>	<b>股份</b>		
Weighted average number of ordinary shares in issue during the period used in the basic loss per share calculation	用於計算每股基本虧損的期間已發行普通股加權平均數目	<b>946,298,370</b>	946,298,370

### 9. PROPERTY, PLANT AND EQUIPMENT

No impairment losses were recognised in respect of property, plant and equipment for both periods. During the period, additions to property, plant and equipment amounted to RMB1,071,000 (six months ended 30 June 2022: RMB1,459,000).

### 9. 物業、廠房及設備

並無就兩個期間確認物業、廠房及設備的減值虧損。於本期內,物業、廠房及設備添置為人民幣1,071,000元(截至2022年6月30日止六個月:人民幣1,459,000元)。

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 10. INVENTORIES

### 10. 存貨

		<b>30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)</b>	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (audited) (經審核)
Raw materials	原材料	<b>40,163</b>	29,407
Work-in-progress	在製品	<b>4,281</b>	412
Finished goods	製成品	<b>69,317</b>	45,179
Goods merchandise	採購品	<b>276</b>	274
		<b>114,037</b>	75,272

### 11. TRADE RECEIVABLES

### 11. 貿易應收款項

		<b>30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)</b>	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (audited) (經審核)
Trade receivables	貿易應收款項	<b>35,093</b>	30,858
Impairment	減值	<b>(3,069)</b>	(2,674)
		<b>32,024</b>	28,184

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 11. TRADE RECEIVABLES (CONTINUED)

An ageing analysis of trade receivables as at the end of reporting period, based on the invoice date and net of loss allowance, is as follows:

		<b>30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)</b>	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (audited) (經審核)
Within 1 month	1個月內	<b>20,541</b>	14,078
Over 1 month but within 3 months	1至3個月	<b>7,643</b>	11,739
Over 3 months but within 1 year	3個月至1年	<b>3,733</b>	1,983
Over 1 year	1年以上	<b>107</b>	384
		<b>32,024</b>	28,184

The movements in the loss allowance for impairment of trade receivables are as follows:

		<b>30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)</b>	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (audited) (經審核)
At beginning of the year	年初	<b>2,674</b>	2,361
Impairment losses accrued	累計減值虧損	<b>424</b>	655
Amount written off as uncollectible	撇銷為不可收回款項	<b>(32)</b>	(371)
Exchange realignment	匯兌調整	<b>3</b>	29
		<b>3,069</b>	2,674

### 11. 貿易應收款項(續)

於報告期末，按發票日期及扣除虧損撥備的貿易應收款項的賬齡分析如下：

貿易應收款項減值的虧損撥備變動如下：



# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 12. PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES

### 12. 預付款項、按金及其他應收款項

		<b>30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)</b>	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (audited) (經審核)
Prepayments	預付款項	<b>12,202</b>	10,939
Right-of-return assets	退貨權資產	<b>32</b>	44
Deposits and other receivables	按金及其他應收款項	<b>3,996</b>	4,799
Value-added tax recoverable	可收回增值稅	<b>1,754</b>	288
		<b>17,984</b>	16,070

None of the above assets is either past due or impaired. The financial assets included in the above balances relate to receivables for which there was no recent history of default.

概無前述資產逾期或減值。計入前述結餘的金融資產涉及近期並無違約記錄的應收款項。

### 13. CASH AND CASH EQUIVALENTS

For the purpose of the interim condensed statement of cash flows, cash and cash equivalents are comprised of the followings:

### 13. 現金及現金等價物

就中期簡明現金流量表而言，現金及現金等價物由以下各項組成：

		<b>30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)</b>	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (audited) (經審核)
Cash and bank balance	現金及銀行結餘	<b>47,622</b>	57,462
Time deposits	定期存款	<b>13,164</b>	17,279
		<b>60,786</b>	74,741
Less: Restricted cash	減：受限制現金	-	(1,350)
Cash and cash equivalents	現金及現金等價物	<b>60,786</b>	73,391

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 14. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

		<b>30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)</b>	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (audited) (經審核)
Within 1 month	1個月內	<b>26,081</b>	10,541
Over 1 month but within 3 months	1至3個月	<b>4,947</b>	9,907
Over 3 months but within 1 year	3個月至1年	<b>126</b>	361
Over 1 year	1年以上	<b>681</b>	719
		<b>31,835</b>	21,528

The trade payables are non-interest-bearing and are normally settled on terms between 30 and 90 days.

### 14. 貿易應付款項

於報告期末，按發票日期的貿易應付款項的賬齡分析如下：

		<b>30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)</b>	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (audited) (經審核)
Within 1 month	1個月內	<b>26,081</b>	10,541
Over 1 month but within 3 months	1至3個月	<b>4,947</b>	9,907
Over 3 months but within 1 year	3個月至1年	<b>126</b>	361
Over 1 year	1年以上	<b>681</b>	719
		<b>31,835</b>	21,528

貿易應付款項為免息及一般按30至90天的期限結算。

### 15. OTHER PAYABLES AND ACCRUALS

		<b>30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)</b>	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (audited) (經審核)
Contract liabilities	合約負債	<b>8,363</b>	13,923
Refund liabilities	退款負債	<b>1,260</b>	4,752
Other payables	其他應付款項	<b>5,232</b>	5,274
Accrued payroll	應計薪酬	<b>9,417</b>	15,743
Other tax payables	其他應付稅項	<b>1,250</b>	1,409
		<b>25,522</b>	41,101

Other payables are non-interest-bearing.

### 15. 其他應付款項及應計費用

其他應付款項並無計息。

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 16. SHARE CAPITAL

### 16. 股本

		<b>30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)</b>	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (audited) (經審核)
Issued and fully paid:	已發行及繳足：		
946,298,370 (2022: 946,298,370) ordinary shares	946,298,370 股 (2022 年： 946,298,370 股) 普通股	<b>94,630</b>	94,630

### 17. DISPOSAL OF A SUBSIDIARY

### 17. 出售一間附屬公司

On 24 April 2023, the Group entered into a sale and purchase agreement to dispose of its entire interest in Nanjing Buy-In-House Ecommerce Co Ltd ("Zhaiyigou"), a wholly-owned subsidiary, to Ms. Zhang Tinghua, one former shareholder of the Group, who sold out all her shares in the Group on 13 June 2023. The disposal had been completed in May 2023. The assets and liabilities of Zhaiyigou at the disposal date were as follows:

於2023年4月24日，本集團訂立買賣協議，向本集團一名前股東張婷花女士出售其於全資附屬公司南京宅易購電子商務有限公司（「宅易購」）的全部權益，張婷花女士於2023年6月13日出售其於本集團的全部股份。出售事項已於2023年5月完成。於出售日期，宅易購的資產及負債如下：

		<b>2023 2023年 RMB'000 人民幣千元 (unaudited) (未經審核)</b>
Net assets disposed of:	已出售資產淨值：	
Cash and cash equivalents	現金及現金等價物	<b>40</b>
Other receivables	其他應收款項	<b>1</b>
Other payables and accruals	其他應付款項及應計費用	<b>(92)</b>
		<b>(51)</b>
Gain on disposal of a subsidiary	出售一間附屬公司的收益	<b>61</b>
		<b>10</b>
Satisfied by:	以下列方式支付：	
Cash	現金	<b>10</b>
		<b>10</b>
An analysis of the net inflow of cash and cash equivalents in respect of the disposal of a subsidiary is as follows:	就出售一間附屬公司的現金及現金等價物淨流入分析如下：	
Cash consideration	現金代價	<b>10</b>
Cash and bank balances disposed of	已出售現金及銀行結餘	<b>40</b>
		<b>(30)</b>

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 18. RELATED PARTY DISCLOSURES

- (a) The Group had the following transactions with related parties during the year:

During the period, the Group disposed a subsidiary, Zhaiyigou at a consideration of RMB10,000, to Ms. Zhang Tinghua, one former shareholder of the Group, who sold out all her shares in the Group on 13 June 2023. Further details of the transaction are included in note 17 to the interim condensed consolidated financial information. (2022: Nil).

- (b) Compensation of key management personnel of the Group:

### 18. 關聯方披露

- (a) 本集團於年內與關聯方進行以下交易：

期內，本集團以代價人民幣10,000元向本集團一名前股東張婷花女士出售一間附屬公司宅易購，張婷花女士於2023年6月13日出售其於本集團的全部股份。有關交易的進一步詳情載於中期簡明綜合財務資料附註17(2022年：無)。

- (b) 本集團主要管理層人員的薪酬：

		For the Six months ended 30 June 截至6月30日止六個月	
		2023 2023年 RMB'000 人民幣千元 (unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (unaudited) (未經審核)
Basic salaries and bonus	基本薪資及花紅	4,244	2,585
Social insurance and housing fund	社會保險及住房公積金	81	83
		<b>4,325</b>	2,668



# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 19. FINANCIAL ASSETS AND FINANCIAL LIABILITIES

Set out below is an overview of financial assets, other than cash and cash equivalents, held by the Group as at 30 June 2023 and 31 December 2022:

### 19. 金融資產及金融負債

以下是本集團於2023年6月30日及2022年12月31日所持金融資產(現金及現金等價物除外)的概況：

		<b>30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)</b>	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (audited) (經審核)
<b>Financial assets at amortised cost:</b>	<b>按攤銷成本入賬的金融資產：</b>		
Trade receivables	貿易應收款項	<b>32,024</b>	28,184
Financial assets included in prepayments, deposits and other receivables	列入預付款項、按金及其他應收款項的金融資產	<b>3,996</b>	4,799
Cash and cash equivalents	現金及現金等價物	<b>60,786</b>	73,391
Restricted cash	受限制現金	-	1,350
		<b>96,806</b>	107,724

		<b>30 June 2023 2023年 6月30日 RMB'000 人民幣千元 (unaudited) (未經審核)</b>	31 December 2022 2022年 12月31日 RMB'000 人民幣千元 (audited) (經審核)
<b>Financial liabilities at amortised cost</b>	<b>按攤銷成本入賬的金融負債</b>		
Trade payables	貿易應付款項	<b>31,835</b>	21,528
Financial liabilities included in other payables and accruals	列入其他應付款項及應計費用的金融負債	<b>5,232</b>	5,274
		<b>37,067</b>	26,802

# NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 中期簡明綜合財務報表附註

For the six months ended 30 June 2023 截至2023年6月30日止六個月

### 20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

The carrying amounts of the Group's financial instruments are reasonably approximate to the fair values.

Management has assessed that the fair values of trade receivables, financial assets included in prepayments, deposits and other receivables, trade payables, financial liabilities included in other payables and accruals. The differences are immaterial since the fair values are mainly equal to their carrying amounts.

### 21. EVENTS AFTER THE REPORTING PERIOD

There is no significant subsequent event undertaken by the Group after 30 June 2023.

### 20. 金融工具公允價值及公允價值等級

本集團金融工具的賬面值與公允價值合理相若。

管理層評估貿易應收款項、計入預付款項、按金及其他應收款項的金融資產、貿易應付款項、計入其他應付款項及應計費用的金融負債的公允價值。由於公允價值大致上等於其賬面值，故差額並不重大。

### 21. 報告期後事項

於2023年6月30日後，本集團並無進行任何重大期後事項。



南京中生聯合股份有限公司  
NANJING SINOLIFE UNITED COMPANY LIMITED\*

